| Filed On | Filing |
|---|---|
| 13 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 | 10-Q |
| 12 Nov 2026 | 8-K: Results of Operations and Financial Condition |
| 06 Nov 2026 |
Form 3: Wartell Michael J., Director
No securities owned |
| 06 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
I am pleased to nominate you as a member of the board of directors (the “Board”) of Fractyl Health, Inc., a Delaware corporation (the “Company”). |
| 22 Oct 2026 |
8-K: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation +1 more
Fractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance |
| 16 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
October 2026 REMAIN-1 Pivotal Study Positive Topline 6 Month Results for Revita in Post-GLP-1 Weight Maintenance Revita is for investigational use only in the United States. Revita has a CE mark in the EU/UK. REMAIN-1 is an ongoing study... |
| 13 Oct 2026 | SCHEDULE 13G |
| 01 Oct 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
Fractyl Health, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), certifies: |
| 24 Sep 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On September 24, 2026, Fractyl Health, Inc. (the “Company”) held its Special Meeting of Stockholders (the “Special Meeting”). Of the 159,179,848, shares of the Company’s common stock outstanding as of the record date of August 21, 2026, ... |
| 16 Sep 2026 |
Form 4: Bradley William, Director
Bought 64,516 shares ($39.9K) |
| 11 Sep 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
As previously disclosed, on March 13, 2026, Fractyl Health, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common ... |
| 24 Aug 2026 | DEF 14A |
| 14 Aug 2026 | PRE 14A |
| 10 Aug 2026 | 10-Q |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition
One-year REMAIN-1 Midpoint Cohort data show Revita patients maintained up to 84% of prior GLP-1-induced weight loss versus 46% with sham in patients receiving complete duodenal ablations — the first randomized evidence of durable, drug-f... |
| 15 Jul 2026 |
8-K: Regulation FD Disclosure; Other Events
Positive One-Year Randomized REMAIN-1 Midpoint Cohort Results July 15, 2026 Revita is for investigational use only in the United States. Revita has a CE mark in the EU/UK. Exhibit 99.2 |
| 15 Jun 2026 |
Form 4: Royan Ajay, Director
Bought 23,000 shares ($19.6K) |
| 11 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 10, 2026, Fractyl Health, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 158,648,963 shares of the Company’s common stock outstanding as of the record date of April 17, 2026, 112,... |
| 11 Jun 2026 |
Form 4: Bradley William, Director
Bought 68,493 shares ($50.3K) · Granted 22,500 Stock Option |
Loading...